FluxMPS™ Medium 199 w/ Earle’s salts and 25mM HEPES buffer w/o Sodium Pyruvate: 1X Liquid
FluxMPS™ Medium 199 w/ Earle's salts and 25 mM HEPES buffer w/o Sodium Pyruvate: 1X Liquid
FluxMPS™ DCP-M199H-P1X is a Microfluidics Suitable formulation of the historically significant Medium 199 — the first nutritionally defined cell culture medium — adapted for organ-on-a-chip (OoC), primary cell culture, vaccine/virus production, and microfluidic platforms. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.
- Dual-stage filtration: 0.1 µm pre-filtration + 0.04 µm final filter, reaching a 0.04 µm microchannel-safe cut-off
- Endotoxin release specification < 0.05 EU/mL (USP <85> BET, batch-tested)
- Low Glucose (1,000 mg/L) + L-Glutamine (100 mg/L) + Sodium Bicarbonate + 25 mM HEPES + Earle's Salts; no Sodium Pyruvate added
- Dual-buffered system (sodium bicarbonate + 25 mM HEPES) supporting stable pH 7.4 across a range of CO₂ conditions
- ISO Class 5 (Class 100) aseptic fill & finish
- ISO 13485:2016 quality management system; 21 CFR Part 820 (QMSR) aligned
- USP <788> Method 1 (light obscuration) particulate compliance on every production lot
- Custom pyruvate, glucose, and HEPES concentrations available on request — contact support@diagnocine.com
- Formulation[+] L-Gln [+] NaHCO₃ [+] Phenol Red [+] 25mM HEPES [+] Ca [+] Mg [+] Low Glucose [−] Na Pyruvate
- Glucose1,000 mg/L (Low Glucose)
- L-Glutamine100.000 mg/L
- Sodium PyruvateNot added
- pH (USP <791>)7.4
- Osmolality (USP <785>)285–325 mOsm/kg H₂O
- Endotoxin (USP <85>)< 0.05 EU/mL
- Filtration0.1 µm ×1 + 0.04 µm ×1 (dual-stage)
- Storage2–8 °C, protect from light
- Shelf Life12 months from date of manufacture, unopened
Engineered where standard media fails
Conventional 0.22 µm-filtered Medium 199 can carry subvisible particulates, mycoplasma-sized debris (0.2–0.3 µm), and uncontrolled endotoxin that corrupt primary cell behavior, distort vaccine production yields, and accumulate in microfluidic channels. FluxMPS™ DCP-M199H-P1X addresses these failure modes through a dual-stage filtration process and micro-batch ISO Class 5 production.
Microchannel-Safe Purity
A 0.04 µm final filter removes particulates that would otherwise accumulate in organ-on-a-chip and microfluidic channels. USP <788> Method 1 (light obscuration) particulate compliance is verified on every production lot.
Defined Metabolic Control
Low glucose (1,000 mg/L) with 25 mM HEPES supports primary cells, non-transformed lines, and vaccine production while reducing dependence on bicarbonate-only buffering.
Ultrapure Type 1 Water
All formulation uses 18.2 MΩ·cm Type 1 water, controlled for trace metals and organic carbon (TOC), supporting sensitive electrophysiology, TEER, and biosensor-based OoC readouts.
Low Background for Imaging
An ultra-low particulate baseline (USP <788> Method 1 compliant) reduces particulate-associated background in confocal and widefield microscopy, and lowers optical noise in inline chip biosensors.
Rich, Stable Nutrient Profile
Medium 199's comprehensive formulation — including nucleotides, vitamins, nucleosides, HEPES, and Earle's salts — supports demanding primary and non-transformed cell culture with micro-batch consistency.
Customization On Demand
Sodium pyruvate, glucose concentration, HEPES level, and other nutrients adjustable on request. Contact support@diagnocine.com.
Dual-stage filtration system
FluxMPS™ DCP-M199H-P1X undergoes a validated two-stage membrane filtration process — a 0.1 µm pre-filter followed by a 0.04 µm final filter — reaching a 0.04 µm microchannel-safe cut-off. The pre-filter protects the final filter from premature fouling, delivering a substantially lower particulate burden than single-pass 0.22 µm filtration.
-
1
0.1 µm Prefiltration
Removes large particulates and aggregates and provides 0.1 µm mycoplasma-retentive filtration (not tested per lot). Protects the downstream 0.04 µm final filter from premature fouling.
-
2
0.04 µm Final filtration — Polish
Retains fine particulates and sub-micron aggregates that pass a 0.22 µm filter. Aseptic fill is completed under ISO Class 5 laminar-flow conditions.
Performance vs. conventional media
Particulate testing per USP <788> Method 1 (light obscuration) supports a substantially lower subvisible particle burden for FluxMPS™ Medium 199 relative to standard single-pass 0.22 µm-filtered Medium 199. This reduces channel occlusion risk and supports higher signal fidelity in biosensor-equipped chip systems.
© Diagnocine® — DCP-M199H-P1X
Validated applications for FluxMPS™ Medium 199
Originally developed by Morgan, Morton, and Parker (1950), Medium 199 remains a standard for primary cell nutrition. FluxMPS™ DCP-M199H-P1X extends this heritage to MPS, OoC, and microfluidic platforms requiring endotoxin-controlled, low-particulate media.
Automated Bioreactors & Robotics
For automated perfusion bioreactors and robotic liquid-handling systems, an optional 0.01 µm (10 nm) MPS Grade variant of FluxMPS™ Medium 199 is available on inquiry. This grade targets nano-aggregates that can foul precision valve seats, inline optical sensors, and pump mechanisms.
- Total Particulate Exclusion: 0.01 µm filtration removes aggregates not addressed by 0.04 µm membranes, protecting sensitive automation hardware.
- Valve & Sensor Protection: Cleaner media can extend service intervals of solenoid valves, bubble detectors, and inline optical sensors in automated systems.
- Extended Perfusion Stability: Consistent, low-particulate perfusion supports primary cell viability over multi-week continuous culture.
Inquiry Required: The 0.01 µm MPS Grade is manufactured on request. Contact support@diagnocine.com for volume, lead time, and pricing.
Micro Physiological System (MPS) & Chip
Low-particulate Medium 199 for epithelial, endothelial, and primary cell chip models. HEPES buffering supports stable pH in open microfluidic environments.
Vaccine & Virus Production
Medium 199's original design for primary chick embryo fibroblasts makes it a standard for vaccine research. FluxMPS™ purity supports viral yield reproducibility.
iPSC-Derived & Primary Cell Models
Endotoxin-controlled Medium 199 supports primary explants of epithelial cells and iPSC-derived models requiring a defined nutritional environment.
Endothelial & Primary Cells
Endotoxin <0.05 EU/mL supports endothelial monolayer and vascular chip studies where endotoxin-driven artifacts are a concern. Earle's salts provide a physiological ionic environment.
Metabolic Flux Analysis
Low glucose (1,000 mg/L) and the absence of sodium pyruvate enable isotope-traced metabolic flux experiments without confounding exogenous pyruvate carbon. Not compatible with Agilent Seahorse XF assays, which require bicarbonate-free, phenol red-free medium.
Microscopy & Optical Sensing
An ultra-low particulate baseline reduces particulate-related background in confocal and biosensor-based chip imaging applications.
Complete technical specifications
All specifications are per-lot release targets. Certificate of Analysis (CoA) available on request at support@diagnocine.com.
| Parameter | Specification |
|---|---|
| Formulation | [+] L-Glutamine [+] Sodium Bicarbonate [+] Phenol Red [+] 25mM HEPES [+] Calcium [+] Magnesium [+] Low Glucose [−] Sodium Pyruvate |
| Appearance | Orange to red-colored, clear liquid |
| pH (USP <791>) | 7.4 USP <791> |
| Osmolality (USP <785>) | 285–325 mOsm/kg H₂O USP <785> |
| Glucose | 1,000 mg/L (Low Glucose) |
| L-Glutamine | 100.000 mg/L |
| Sodium Pyruvate | Not included |
| Phenol Red | Included (15 mg/L, disodium salt) |
| Parameter | Specification |
|---|---|
| Endotoxin (USP <85> BET) | < 0.05 EU/mL USP <85> |
| Sterility (USP <71>) | No growth after 14 days incubation USP <71> |
| Mycoplasma | 0.1 µm mycoplasma-retentive filtration (not tested per lot) |
| Particulate ≥10 µm (USP <788> Method 1) | Compliant USP <788> |
| Particulate ≥25 µm (USP <788> Method 1) | Compliant USP <788> |
| Water purity | Ultrapure Type 1, 18.2 MΩ·cm (trace-metal & TOC controlled) |
| Manufacturing std. | ISO 13485:2016 ISO 13485 |
| Fill environment | ISO Class 5 (Class 100) laminar flow |
| Parameter | Specification |
|---|---|
| Storage temperature | 2–8 °C, protect from bright light |
| Freeze-thaw | Do not freeze |
| Shelf life | 12 months from date of manufacture, unopened |
| Shipping condition | Cold pack (2–8 °C) |
| CO₂ requirement | Approximately 5–6% CO₂ (calculated from 26 mM sodium bicarbonate); 25 mM HEPES provides supplemental buffering for reduced CO₂-dependence |
| Parameter | Specification |
|---|---|
| Raw material grade | Analytical / USP-grade reagents |
| Traceability | Full lot traceability per ISO 13485 |
| Manufacturing QMS | ISO 13485:2016 certified ISO 13485 |
| UNSPSC | 41116155 — Molecular biology and cell culture growth media (UNv260801) |
| Regulatory alignment | 21 CFR Part 820 (QMSR) aligned |
| Production method | Micro-batch aseptic manufacturing |
| Intended use | Research Use Only (RUO) |
Full composition (mg/L)
This formulation contains 62 individual components across 4 categories (Inorganic Salts, Amino Acids, Vitamins, Others). All values are per-lot release targets confirmed on the CoA.
| Component | CAS Number | mg/L |
|---|---|---|
| INORGANIC SALTS | ||
| Calcium chloride dihydrate | 10035-04-8 | 265.000 |
| Ferric nitrate nonahydrate | 7782-61-8 | 0.720 |
| Magnesium sulfate anhydrous | 7487-88-9 | 97.720 |
| Potassium chloride | 7447-40-7 | 400.000 |
| Sodium acetate anhydrous | 127-09-3 | 50.000 |
| Sodium bicarbonate | 144-55-8 | 2200.000 |
| Sodium chloride | 7647-14-5 | 6800.000 |
| Sodium phosphate monobasic | 7558-80-7 | 122.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| AMINO ACIDS | ||
| Glycine | 56-40-6 | 50.000 |
| L-Alanine | 56-41-7 | 25.000 |
| L-Arginine hydrochloride | 1119-34-2 | 70.000 |
| L-Aspartic acid | 56-84-8 | 30.000 |
| L-Cysteine hydrochloride monohydrate | 7048-04-6 | 0.100 |
| L-Cystine dihydrochloride | 30925-07-6 | 26.000 |
| L-Glutamic acid | 56-86-0 | 67.000 |
| L-Glutamine | 56-85-9 | 100.000 |
| L-Histidine hydrochloride monohydrate | 5934-29-2 | 22.000 |
| L-Hydroxyproline | 51-35-4 | 10.000 |
| L-Isoleucine | 73-32-5 | 20.000 |
| L-Leucine | 61-90-5 | 60.000 |
| L-Lysine hydrochloride | 657-27-2 | 70.000 |
| L-Methionine | 63-68-3 | 15.000 |
| L-Phenylalanine | 63-91-2 | 25.000 |
| L-Proline | 147-85-3 | 40.000 |
| L-Serine | 56-45-1 | 25.000 |
| L-Threonine | 72-19-5 | 30.000 |
| L-Tryptophan | 73-22-3 | 10.000 |
| L-Tyrosine disodium salt dihydrate | 69847-44-5 | 57.660 |
| L-Valine | 72-18-4 | 25.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| VITAMINS | ||
| Ascorbic acid | 50-81-7 | 0.050 |
| Calciferol | 50-14-6 | 0.100 |
| Choline chloride | 67-48-1 | 0.500 |
| D-Biotin | 58-85-5 | 0.010 |
| D-Ca-Pantothenate | 137-08-6 | 0.010 |
| DL-Tocopherol phosphate | 5765-44-6 | 0.010 |
| Folic acid | 59-30-3 | 0.010 |
| Menadione | 58-27-5 | 0.010 |
| Niacinamide | 98-92-0 | 0.025 |
| Nicotinic acid | 59-67-6 | 0.025 |
| Pyridoxal hydrochloride | 65-22-5 | 0.025 |
| Pyridoxine hydrochloride | 58-56-0 | 0.025 |
| Retinol Acetate | 127-47-9 | 0.140 |
| Riboflavin | 83-88-5 | 0.010 |
| Thiamine hydrochloride | 67-03-8 | 0.010 |
| i-Inositol | 87-89-8 | 0.050 |
| p-Amino benzoic acid (PABA) | 150-13-0 | 0.050 |
| OTHERS | ||
| Adenine sulfate | 321-30-2 | 10.000 |
| Adenosine triphosphate | 987-65-5 | 1.000 |
| Adenosine monophosphate | 61-19-8 | 0.200 |
| Cholesterol | 57-88-5 | 0.200 |
| Deoxyribose | 533-67-5 | 0.500 |
| Glucose | 50-99-7 | 1000.000 |
| Glutathione reduced | 70-18-8 | 0.050 |
| Guanine hydrochloride | 635-39-2 | 0.300 |
| HEPES Buffer | 7365-45-9 | 5958.000 |
| Hypoxanthine sodium salt | 5765-44-6 | 0.354 |
| Phenol red disodium salt | 34487-61-1 | 15.000 |
| Polysorbate 80 | 9005-65-6 | 4.900 |
| Ribose | 50-69-1 | 0.500 |
| Thymine | 65-71-4 | 0.300 |
| Uracil | 66-22-8 | 0.300 |
| Xanthine | 69-89-6 | 0.344 |
Manufacturing & compliance overview
Every FluxMPS™ Medium 199 lot is manufactured under an ISO 13485:2016 quality management system with raw-material traceability, dual-stage filtration, and batch-level endotoxin verification.
ISO 13485:2016 QMS
Manufactured under an ISO 13485-certified quality management system. All final QA, testing, and packaging performed at the Diagnocine R&D and Quality Testing Center, Totowa, New Jersey, USA.
Ultrapure Type 1 Water
All formulation uses 18.2 MΩ·cm Type 1 water, controlled for trace metals and organic carbon (TOC), supporting sensitive biosensor and electrophysiology-based readouts.
ISO Class 5 Fill & Finish
Aseptic filling inside ISO Class 5 (Class 100) laminar-flow enclosures, supporting particulate and bioburden control consistent with injectable-grade manufacturing practices.
Micro-Batch Precision
Small-batch production enables per-batch QC verification, tighter lot-to-lot consistency, and faster turnaround for custom formulation requests. Each batch is individually tested and released.
Endotoxin — USP <85> BET
LAL assay per manufacturing batch. Release specification: < 0.05 EU/mL. See batch-level quality control note below.
Particulate — USP <788> Method 1
Light-obscuration particle counting verifies ≤10 µm and ≤25 µm particulate limits, supporting microchannel-safe purity per batch.
Osmolality — USP <785>
Freezing-point depression osmometry per USP <785>. Specification: 285–325 mOsm/kg H₂O. Lot-specific values on CoA.
Documentation & CoA
Full Certificate of Analysis including pH, osmolality, endotoxin, sterility, and particulate data for every lot. Request via support@diagnocine.com.
- Endotoxin — LAL assay, USP <85> Bacterial Endotoxins Test; assay sensitivity 0.005 EU/mL; release specification < 0.05 EU/mL
- pH, osmolality, conductivity, appearance and clarity
- Sterility
How DCP-M199H-P1X compares
FluxMPS™ Medium 199 versus conventional 0.22 µm and 0.1 µm filtered alternatives.
| Parameter | DCP-M199H-P1X (FluxMPS™) | Conventional Medium 199 (0.22 µm) | Standard Medium 199 (0.1 µm) |
|---|---|---|---|
| Grade | Microfluidics Suitable | Standard grade | Standard grade |
| Distinctive formulation | 25 mM HEPES + Earle's Salts; no Pyruvate | Variable; often includes pyruvate | Variable |
| Final filtration pore size | 0.04 µm | 0.22 µm | 0.1 µm |
| Number of filtration stages | 2 stages | 1 stage | 1–2 stages |
| Mycoplasma barrier filtration | check_circle | cancel | check_circle |
| Endotoxin (release specification) | FluxMPS™ — < 0.05 EU/mL | Corning classical liquid media — < 0.25 EU/mL Sigma-Aldrich DMEM complete medium — ≤ 2 EU/mL Gibco classical DMEM — Not specified (recorded per lot) |
|
| USP particulate compliance | check_circle USP <788> Method 1 | cancel | cancel |
| Water quality | Ultrapure 18.2 MΩ·cm | Purified water | Purified water |
| Manufacturing QMS | ISO 13485:2016 | Standard GMP | Standard GMP |
| Microfluidic channel compatibility | check_circle | cancel | Partial |
| Custom formulation | check_circle | Limited | Limited |
Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".
Frequently asked questions
Common questions about FluxMPS™ DCP-M199H-P1X performance, compatibility, and ordering.
Supporting literature
Curated peer-reviewed references supporting Medium 199 use in primary cells, virus production, microfluidic platforms, and organ-on-a-chip applications.
- Morgan JF, Morton HJ, Parker RC. Nutrition of animal cells in tissue culture. I. Initial studies on a synthetic medium. Proc Soc Exp Biol Med. 1950;73(1):1–8. doi:10.3181/00379727-73-17557
- Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–772. doi:10.1038/nbt.2989
- Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662–1668. doi:10.1126/science.1188302
- Ramzy PI, et al. Establishment of epithelial cell lines from primary human explants using serum-free medium. In Vitro Cell Dev Biol Anim. 1996;32(1):29–35. doi:10.1007/BF02723028
- Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov. 2015;14(4):248–260. doi:10.1038/nrd4539
- Langford RM, et al. Mycoplasma contamination in cell culture: prevention strategies and detection. Cytotechnology. 2018;70(1):27–34. doi:10.1007/s10616-017-0128-6
- Maoz BM, et al. A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells. Nat Biotechnol. 2018;36(9):865–877. doi:10.1038/nbt.4226
- Nawroth JC, et al. Breathing microfluidic organ-on-a-chip. Sci Adv. 2020;6(30):eaaw7505. doi:10.1126/sciadv.aaw7505
- Williamson A, et al. The future of the patient-specific body-on-a-chip. Lab Chip. 2013;13(18):3471–3480. doi:10.1039/c3lc50237f
- Kaur G, Dufour JM. Cell lines: valuable tools or useless artifacts. Spermatogenesis. 2012;2(1):1–5. doi:10.4161/spmg.19885
